Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine for Psychotic-Like Symptoms in Borderline Personality Disorder
NCT00254748Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in borderline personality disorder (BPD) comparing Placebo with Quetiapine (2 arms). Primary endpoint: Effect of quetiapine on psychotic-like symptoms and severity of psychiatric symptoms at 8 weeks. Started Jun 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT00254748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254748.